A study for patients who have completed a prior global Novartis sponsored ceritinib (LDK378) study and are judged by the investigator to benefit from continued treatment

Mise à jour : Il y a 5 ans
Référence : EUCTR2015-001922-40

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To allow continued treatment to patients receiving ceritinib in existing Novartis sponsored studies which have fulfilled the requirements for the primary objective, and in the opinion of the investigator, would benefit from continued treatment.


Critère d'inclusion

  • non-small cell lung cancer